Nemysis

Our goal is to create long-term and mutually respectful and beneficial relationships with all levels of those in the medical/bio-pharma research field. We are also developing a pioneering delivery matrix which is designed to provide gastro-protection to deliver enzymes and other compounds, that are designed to work in the GI tract beyond the stomach, to the site of action in the small intestines. We focus on bioactive substances, and actively explore opportunities where we have identified large market potentials, coupled with unmet patient needs, and we can identify and harness innovative solutions. With a specific emphasis on preserving the microbiome , we developed an iron-based nano-particulate compound to address the effects caused by iron deficiency as well as the currently available therapeutic solutions. E40 is a new Glutenase, developed to specifically address these conditions. We operate a diversified, independent platform with multi-product capabilities. In the short term we take products through the novel food supplement or medical device route, but with a longer term plan to take these compounds to drug status and to be phase II, ready to out-license products for drug development for the prescriptions market. In order to do this all our pre-clinical, clinical and manufacturing development activities are carried out, through any development stage, in GLP and GMP standard.